The IAS Towards an HIV Cure Team is excited to share the announcement of a common Material Transfer Agreement (cMTA), developed by the initiative
Industry Collaboration Group, whose mission is to foster dialogue and collaboration between the private and public sector involved in HIV cure research.
The IAS issued a
press release on January 20, 2016, announcing the agreement, approved by ViiV Healthcare, Gilead, Bristol-Myers Squibb, Johnson & Johnson, and Merck. The cMTA represents a major achievement to accelerate research for a remission and ultimately cure for HIV by facilitating the access to combinational use of marketed compounds in antiretroviral therapy for preclinical studies.
The cMTA is the result of lengthy discussions and negotiations among the pharmaceutical companies involved. The IAS Towards an HIV Cure Team is delighted that the outcome of this collaborative effort is available to the broad scientific community, and sincerely hopes that you and your colleagues will be able to make use of this cMTA for research towards an HIV cure.
Thank you to all the members of the Industry Collaboration Group, in particular the company representatives and the co-chairs, for leading this truly collaborative effort.